On September 18, 2012, a new study published in the Annals of Internal Medicine found thalidomide (Thalomid) from Celgene was...
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Revlimid (lenalidomide) from Celgene, for people...
Celgene Corp has warned doctors in the UK that Imnovid (pomalidomide) which is newly approved for Multiple Myeloma can cause...
New data from a Phase III study (FIRST) of Revlimid (lenalidomide), from Celgene, in combination with dexamethasone in patients newly...
Celgene International S�rl, announced updated results of its pivotal phase III FIRST (MM-020/IFM 07-01) trial, comparing continuous Revlimid (lenalidomide) plus...
A Phase III study (MM-020/IFM 07-01) of Revlimid (lenalidomide), from Celgene, in combination with dexamethasone in patients newly diagnosed with...
The FDA on 8 February 2013, approved Pomalyst (pomalidomide), from Celgene, to treat patients with Multiple Myeloma whose disease progressed...
The FDA has expanded the existing indication for Revlimid (lenalidomide), from Celgene Corp, in combination with dexamethasone to include patients...
Thalidomide BMS in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide BMS Pregnancy Prevention Programme (see section 4.4).
Celgene Corporation announced that data from FIRST (MM-020/IFM 07-01)�an open-label phase III randomized study of continuous Revlimid (lenalidomide) in combination...